9hon MSN
The Highly Anticipated “Triple Agonist” Weight Loss Med Is Almost Here—What Doctors Say About It
Phase 3 clinical trial results are out now.
2026 is likely the year that two new oral weight loss drugs from Novo Nordisk and Eli Lilly will reach patients in the U.S.
GLP-1s mute sugar in our bodies. That's impacting our taste buds.
In November, the Trump administration resurrected a Most Favored Nation (MFN) reference pricing policy, which would tie drug ...
12hon MSN
Is Eli Lilly a Buy Before 2026?
Eli Lilly stock can be a smart addition to a diversified long-term investment portfolio.
Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). In a decade, Eli Lilly could be in the ...
The futures are trading lower after what started as a bounce-back Monday turned into a reversal Monday, as the AI/Datacenter ...
Zacks Investment Research on MSN
Eli Lilly or Merck: Where should investors put their money?
Eli Lilly LLY and Merck MRK are both major global pharmaceutical companies with blockbuster drug portfolios and deep ...
The Brown County Community Foundation is pleased to announce the recipient of the 2026 Lilly Endowment Community Scholarship ...
I am bullish on healthcare stocks, especially pharmaceuticals, due to conservative valuations. Check out the healthcare ...
A federal judicial panel said Monday it would centralize a growing number of lawsuits against Novo Nordisk and Eli Lilly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback